Study of meropenem and pralurbactam for certain antibiotic-resistant infections
Treatments studied
Part of Infections clinical trials.
This trial tests a combination of two antibiotics (meropenem and pralurbactam) for treating serious infections caused by bacteria that are resistant to many other antibiotics. It may be an option for hospitalized patients with pneumonia, urinary tract infections, abdominal infections, or bloodstream infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old and are currently in the hospital.
- You have a confirmed infection caused by carbapenem-resistant Enterobacteriaceae (a type of bacteria that doesn't respond to many common antibiotics).
- Your infection is one of these types: pneumonia (lung infection), complicated urinary tract infection, complicated abdominal infection, or a bloodstream infection.
- You have not received more than 24 hours of appropriate antibiotics for this infection, or your symptoms have not improved after at least 2 days of treatment.
- You are expected to live for at least another 28 days.
- You are not currently taking more than 3 systemic antibiotics and do not need treatment for longer than 21 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new antibiotic (BV100 plus low-dose polymyxin B) against a standard treatment for pneumonia caused by a hard-to-treat bacteria (Acinetobacter baumannii). If you have hospital-acquired or ventilator-associated pneumonia and standard antibiotics aren't working, this study may offer a new option.
This study tests whether a new antibiotic (BV100) combined with other antibiotics works safely and effectively against serious infections caused by drug-resistant Acinetobacter bacteria. It may offer a treatment option when standard antibiotics are not working.
This trial tests a new antibiotic combination (meropenem and pralurbactam) for people with serious infections inside the belly (abdomen). It aims to see if this treatment is safe and works better than current options.
This trial tests two different schedules of a combination of antibiotics (ceftazidime-avibactam plus aztreonam) for people with serious infections caused by bacteria that are hard to treat. It aims to find the best way to give these medicines.
This trial tests a combination of two antibiotics (meropenem and pralurbactam) to see if they work better than other treatments for people with pneumonia that started in the hospital or from a breathing machine. If you qualify, this study might offer you a new treatment option.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
Hear when a new Hospital-acquired Bacterial Pneumonia (HABP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.